The Pharma Letter43m
ALK Abello licenses rights to neffy from ARS Pharma
Danish allergy immunotherapy specialist ALK Abello has entered into a strategic license agreement with US-based ARS ...
The Pharma Letter47m
BRIEF—Eisai updates Leqembi outlook
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi ...